Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner

B‐cell lymphoma 2 (BCL‐2), a crucial member of the anti‐apoptotic BCL‐2 family, is frequently dysregulated in cancer and plays an important role in acute myeloid leukemia (AML). Venetoclax is a highly selective BCL‐2 inhibitor that has been approved by the FDA for treating elderly AML patients. Howe...

Full description

Bibliographic Details
Main Authors: Shujuan Huang, Chenying Li, Xiang Zhang, Jiajia Pan, Fenglin Li, Yunfei Lv, Jingwen Huang, Qing Ling, Wenle Ye, Shihui Mao, Xin Huang, Jie Jin
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Molecular Oncology
Subjects:
abivertinib
AML
BTK‐dependent
venetoclax
Online Access:https://doi.org/10.1002/1878-0261.12742

Internet

https://doi.org/10.1002/1878-0261.12742

Similar Items